McDermott + Bull has successfully placed David O’Toole as Chief Financial Officer at AVITA Medical (NASDAQ: RCEL, ASX: AVH). David will report to and work closely with the CEO, serving as a valued member of the executive leadership team. In this role, he will provide strategic guidance for the company’s accounting, finance, investor relations, and systems ensuring support for ongoing growth and expansion.

David brings over two decades of experience in public accounting, having worked at prestigious firms such as Arthur Andersen and Deloitte. He has also served as a CFO for the past 15 years for publicly held companies in biotech and life sciences — industries where he has focused much of his career.  He has also served as an experienced public company Board Member, holding positions as Audit Committee Chair and Compensation Committee member. David’s expertise includes leadership in performance analysis, strategic planning, acquisitions, divestitures, and successful equity raises on Wall Street. He holds a bachelor degree in accounting from the University of Arizona and has completed the executive training course, “Succeeding as a Strategic CFO” at Harvard Business School.

AVITA Medical is a publicly listed, global regenerative medicine company that provides a novel approach to skin regeneration. The company’s products provide innovative treatment solutions derived from the regenerative properties of a patient’s own skin. AVITA Medical’s proprietary technology has evidence for additional skin applications beyond treating burns, such as chronic and traumatic wounds, scar revision, and vitiligo. Avita Medical is currently listed on both the NASDAQ and ASX exchanges.

This executive search was completed by McDermott + Bull Co-Founder + Managing Partner Chris Bull, Director Anne Terry, Executive Recruiters Julia Markward and CJ Shook, and Senior Research Associate Isabelle Karl.